Qiming Venture Partners led the $50m Series B+ funding round in AusperBio.

Qiming Venture Partners, a venture capital firm, led the $50m Series B+ funding round in AusperBio, a clinical-stage biopharmaceutical company developing oligonucleotide therapies, with participation from CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, Sherpa Capital, and other existing investors. "We are greatly honored by the continued support from our investors. It's a strong vote of confidence in our vision and the progress we've made so far," Dr. Guofeng Cheng, AusperBio co-founder and CEO.